Regen BioPharma (RGBP) 10-K2022 FY Annual report

Filed: 15 Nov 22, 3:36pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: addressed, adipose, alteration, anemia, aplastic, approach, arising, artificial, attack, Attraction, AUGMENTATION, back, barred, Biotech, block, blocked, bone, brake, breast, Brian, CAR, central, challenging, chimeric, Civil, complex, complexity, conventional, critical, damaged, DC, dCellVax, DEDIFFERENTIATION, Depot, differentiate, differentiator, DiffronC, DuroCAR, Ebola, efficiently, Embolization, endothelial, engineered, environment, enzyme, eradicate, extract, failure, feasibility, fewer, genetically, Global, growing, growth, harvested, heal, hematopoietic, HemaXellarate, HemaXellerate, home, hypoplasia, IDO, immature, important, imposed, improving, inactive, incomplete, indoleamine, influence, INNATE, Integral, interior, intravenously, isolate, isolated, kill, line, Liver, lymphatic, lymphocyte, lymphoid, marrow, MD, media, mesenchymal, metastatic, mix, pancytopenia, partial, PARY, pending, peripheral, persistence, PhD, physical, physiological, Placental, play, powerful, premium, prevalence, progenitor, reclassification, Reconstitution, recovery, recruit, red, refractory, regenerated, reimplanted, reinstatement, relapse, repair, repression, resistant, role, satisfactorily, shRNA, simplification, social, solid, Specialist, stromal, surface, surgically, SVF, tCellVax, TLR, tool, translational, trial, unapproved, underdevelopment, VACCINE, vascular, vital, vivo, white

Removed: alleged, alleging, amortized, amounted, Bad, base, Borrower, Caven, chemdiv, complaint, connected, County, court, dated, declaration, default, deficit, delinquency, Denial, Diego, eighty, fourteen, fulfilling, lease, leased, lesser, lessor, life, loaned, million, multiplied, negative, ninety, Pacific, payroll, Plaintiff, retroactive, San, seeking, St, stemming, subleased, subtenant, Superior, tangible, terminate, Todd, Unfair, Variable, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RGBP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Regen Biopharma, Inc. on Form 10-K for the year ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 15, 2022	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer